Single-session alcohol sclerotherapy in benign symptomatic hepatic cysts.
OBJECTIVE
To evaluate the results of single-session alcohol sclerotherapy in benign symptomatic liver cysts.


METHODS
Ten cysts (volume 200-4,800 ml) in 10 patients were treated by percutaneous catheterization and injection of 96% ethanol at a dose of 10% of the cyst volume but never more than 100 ml. The treatment was applied for a maximum of 20 min, after which the alcohol and catheter were removed.


RESULTS
A satisfactory reduction in cyst volume was achieved in all patients. In 8 patients there was a re-accumulation of fluid during the first period after therapy, followed by a significant reduction in volume on later follow-up examinations. Except for pain, there were no complications.


CONCLUSIONS
Sclerotherapy as a single-session procedure resulted in a significant reduction in cyst volume in all 10 patients. The postprocedural re-accumulation of fluid seen in 8 patients proved to be temporary. It was not necessary to repeat the sclerotherapy procedure in any patient.
Larssen
T B
TB
Department of Radiology, Haukeland University Hospital, Bergen, Norway.
Viste
A
A
Jensen
D K
DK
Søndenaa
K
K
Røkke
O
O
Horn
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002404:Catheterization / Q000295:instrumentation; D003560:Cysts / Q000628:therapy*; D000431:Ethanol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005122:Exudates and Transudates; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D008107:Liver Diseases / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000139:chemically induced; D012074:Remission Induction; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015911:Sclerotherapy / Q000009:adverse effects; D013997:Time Factors
D012597:Sclerosing Solutions; D000431:Ethanol